Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant as adjunctive therapy in MDD with insomnia symptoms
NCT04532749Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of seltorexant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Sep 2020; status: terminated.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04532749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532749.